

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS
- *LINES*

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

What is claimed is:

1. An immunopolypeptide that binds to human glucose-6-phosphate isomerase with a dissociation constant of no more than about  $10^{-7}$ .

5

2. An isolated immunoglobulin antibody that specifically binds to human glucose-6-phosphate isomerase

10

3. An immunopolypeptide comprising at least one CDR sequence selected from the group consisting of SEQ ID NO's: 15-56 or a significant homolog thereof.

4. An immunopolypeptide according to claim 3 having a triplet of CDR sequences.

15

5. An immunopolypeptide according to claim 4 wherein each CDR of the triplet is separated from other CDR's by a spacer amino acid sequence.

20

6. An immunopolypeptide according to claim 5 wherein the spacer amino acid sequence is a framework region sequence having an amino acid sequence selected from the group consisting of SEQ ID NO's: 57-108 or a significant homolog thereof.

7. An immunopolypeptide according to claim 6 wherein the CDR's of the triplet are selected from either a light chain group or a heavy chain group.

25

8. An immunopolypeptide according to claim 7 wherein the CDR's are matched according to their Fab source.

9. An immunopolypeptide according to claim 8 wherein the framework region sequence is matched to the Fab source of the CDR triplet.

10. An immunopolypeptide according to claim 9 wherein the amino acid sequence is a  $V_L$  or  $V_H$  fragment of the Fab source of the matched CDR triplet and framework regions.
- 5 11. An immunopolypeptide having an amino acid sequence substantially homologous to a sequence selected from the group consisting of SEQ ID NO's: 1-14.
12. An immunopolypeptide according to claim 11 which is a combination of  $V_L$  and  $V_H$ .
- 10 13. An immunopolypeptide according to claim 11 which further includes at least one constant consensus region.
14. An immunopolypeptide according to claim 13 which is a combination of a light  
15 and heavy chain fragment.
15. An immunopolypeptide according to claim 14 which is an Fab, Fab', F(ab')<sub>2</sub>, Fd, scFv or Fv fragment.
- 20 16. An anti-GPI monoclonal antibody having CDR and framework segments with significant homology to the amino acid sequences set forth in SEQ ID NO's: 15-108.
17. A immunopolypeptide encoded in a bacteriophage that is deposited with the ATCC.
- 25 18. An immunopolypeptide Fab fragment having a light variable chain amino acid sequence selected from the group consisting of SEQ ID NO's: 1-7 and a heavy variable amino acid sequence selected from the group consisting of SEQ ID NO's: 8-14.
- 30 19. An immunopolypeptide Fab fragment having its CDR amino acid sequences of its light chain selected from the group consisting of SEQ ID NO's: 36-56 and its CDR

amino acid sequence of its heavy chain sequence selected from the group consisting of SEQ ID NO's: 15-35.

20. An anti-idiotypic antibody that specifically binds with anti-glucose-6-phosphate  
5 isomerase antibody.

21. An anti-idiotypic antibody according to claim 20 which binds with a  
hypervariable region segment of anti-glucose-6-phosphate antibody

10 22. A second immunopolypeptide that specifically binds with anti-6-phosphate  
isomerase antibody.

23. A second immunopolypeptide according to claim 22 that specifically binds with a  
variable region segment of anti-6-phosphate isomerase.

15 24. An antisense oligonucleotide that specifically hybridizes with a polynucleotide  
encoding anti-glucose-6-phosphate isomerase antibody or encoding glucose-6-phosphate  
isomerase.

20 25. An antisense oligonucleotide according to claim 24 having a non-natural  
modification.

26. An antisense oligonucleotide according to claim 25 having at least one  
thiophosphate group, a base alkylation group or a non-natural base group.

25 27. A conjugate of human glucose-6-phosphate isomerase covalently bonded to,  
complexed with, or associated with, a cytotoxic agent.

28. A composition comprising immobilized human glucose-6-phosphate isomerase.

30 29. A nucleotide sequence encoding an immunopolypeptide according to claim 1.

30. A nucleotide sequence having a sequence selected from the group consisting of SEQ ID NOs: 109-122.
- 5 31. A nucleotide sequence encoding an anti-glucose-6-phosphate isomerase antibody.
32. A nucleotide sequence encoding a humanized chimeric monoclonal antibody according to claim 20.
- 10 33. A pharmaceutical composition comprising an immunopolypeptide of claim 1 and a pharmaceutically acceptable carrier.
34. A pharmaceutical composition comprising an anti-idiotypic antibody according to claim 20 and a pharmaceutically acceptable carrier.
- 15 35. A pharmaceutical composition comprising a second immunopolypeptide according to claim 22 and a pharmaceutically acceptable carrier.
36. A pharmaceutical composition comprising an antisense oligonucleotide according to claim 24 and a pharmaceutically acceptable carrier.
- 20 37. A pharmaceutical composition comprising a conjugate according to claim 27 and a pharmaceutically acceptable carrier.
38. A method for diagnosis of autoimmune disease comprising determining the presence of an immune complex formed by combining the blood sera of a patient with human glucose-6-phosphate isomerase.
- 25 39. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of an immunopolypeptide according to claim 1.
- 30

40. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of a humanized chimeric monoclonal antibody according to claim 20.

5 41. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of a second immunopolypeptide according to claim 22.

42. A method for treatment of a patient having autoimmune disease comprising  
10 administering to the patient an effective amount of a conjugate according to claim 27.

43. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective amount of an antisense oligonucleotide according to claim 24.

15

44. A method for treatment of a patient having autoimmune disease comprising filtering the patient's blood extracorporeally through a filter system containing immobilized human glucose-6-phosphate isomerase.

20 45. A method for treatment of a patient having autoimmune disease comprising administering to the patient an effective desensitizing amount of human glucose-6-phosphate isomerase.

46. An antisense oligonucleotide according to claim 24 which hybridizes with the  
25 nucleotide sequence encoding the antibody.